Arrowstreet Capital Limited Partnership Grows Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Arrowstreet Capital Limited Partnership boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 127.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 906,909 shares of the company’s stock after purchasing an additional 508,498 shares during the period. Arrowstreet Capital Limited Partnership owned about 1.58% of Harmony Biosciences worth $28,658,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of HRMY. Mirae Asset Global Investments Co. Ltd. increased its holdings in Harmony Biosciences by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company’s stock valued at $70,000 after buying an additional 299 shares during the last quarter. Gallacher Capital Management LLC grew its position in shares of Harmony Biosciences by 4.3% in the 2nd quarter. Gallacher Capital Management LLC now owns 9,981 shares of the company’s stock worth $315,000 after acquiring an additional 413 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Harmony Biosciences by 12.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,466 shares of the company’s stock worth $141,000 after acquiring an additional 479 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Harmony Biosciences by 0.4% in the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company’s stock valued at $3,620,000 after acquiring an additional 485 shares during the last quarter. Finally, New York State Teachers Retirement System raised its position in shares of Harmony Biosciences by 1.6% during the 2nd quarter. New York State Teachers Retirement System now owns 32,293 shares of the company’s stock valued at $1,020,000 after acquiring an additional 500 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Trading Up 4.1%

Shares of NASDAQ HRMY opened at $39.83 on Friday. The business has a fifty day simple moving average of $30.78 and a 200-day simple moving average of $33.10. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 12.53, a P/E/G ratio of 0.51 and a beta of 0.80. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.93.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). The firm had revenue of $239.46 million during the quarter, compared to analysts’ expectations of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. Sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analyst Ratings Changes

HRMY has been the topic of several research analyst reports. Wall Street Zen cut Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Needham & Company LLC reissued a “buy” rating and set a $42.00 target price on shares of Harmony Biosciences in a report on Monday, November 24th. HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday. Mizuho lifted their price target on shares of Harmony Biosciences from $39.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.63.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.